MX2023004537A - Compuestos y metodos para el tratamiento de trastornos oculares. - Google Patents

Compuestos y metodos para el tratamiento de trastornos oculares.

Info

Publication number
MX2023004537A
MX2023004537A MX2023004537A MX2023004537A MX2023004537A MX 2023004537 A MX2023004537 A MX 2023004537A MX 2023004537 A MX2023004537 A MX 2023004537A MX 2023004537 A MX2023004537 A MX 2023004537A MX 2023004537 A MX2023004537 A MX 2023004537A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treatment
inflammatory
compounds
Prior art date
Application number
MX2023004537A
Other languages
English (en)
Spanish (es)
Inventor
Yair Alster
Omer Rafaeli
Ian Holmes
Hila Barash
Charles Bosworth
Robert M Burk
Marc Gleeson
Mark Richard Stewart
Jonathan Dunn
Alexander James Nicholls
Original Assignee
Azura Ophthalmics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azura Ophthalmics Ltd filed Critical Azura Ophthalmics Ltd
Publication of MX2023004537A publication Critical patent/MX2023004537A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2023004537A 2020-10-21 2021-10-20 Compuestos y metodos para el tratamiento de trastornos oculares. MX2023004537A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063094793P 2020-10-21 2020-10-21
US202163170988P 2021-04-05 2021-04-05
PCT/IB2021/000707 WO2022084738A2 (en) 2020-10-21 2021-10-20 Compounds and methods for the treatment of ocular disorders

Publications (1)

Publication Number Publication Date
MX2023004537A true MX2023004537A (es) 2023-06-15

Family

ID=81291739

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004537A MX2023004537A (es) 2020-10-21 2021-10-20 Compuestos y metodos para el tratamiento de trastornos oculares.

Country Status (8)

Country Link
EP (1) EP4232149A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023546453A (cg-RX-API-DMAC10.html)
KR (1) KR20230110515A (cg-RX-API-DMAC10.html)
AU (1) AU2021363702A1 (cg-RX-API-DMAC10.html)
CA (1) CA3196145A1 (cg-RX-API-DMAC10.html)
IL (1) IL302173A (cg-RX-API-DMAC10.html)
MX (1) MX2023004537A (cg-RX-API-DMAC10.html)
WO (1) WO2022084738A2 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020212755A1 (en) 2019-04-18 2020-10-22 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
US11459351B1 (en) 2021-04-05 2022-10-04 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
WO2024100454A2 (en) * 2022-11-11 2024-05-16 Azura Ophthalmics Ltd. Composition and methods for improving signs and symptoms of ocular disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005641A1 (en) * 2002-02-15 2004-01-08 Michael Burnet Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
WO2013003731A2 (en) * 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
US11420995B2 (en) * 2017-03-03 2022-08-23 Synovo Gmbh Anti-infective and anti-inflammatory compounds
WO2018215638A1 (en) * 2017-05-26 2018-11-29 Novaliq Gmbh Pharmaceutical compositions comprising azithromycin
AU2020259997B2 (en) * 2019-04-18 2025-08-07 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders

Also Published As

Publication number Publication date
EP4232149A2 (en) 2023-08-30
WO2022084738A2 (en) 2022-04-28
EP4232149A4 (en) 2024-12-11
IL302173A (en) 2023-06-01
WO2022084738A3 (en) 2022-06-30
AU2021363702A1 (en) 2023-06-15
CA3196145A1 (en) 2022-04-28
JP2023546453A (ja) 2023-11-02
KR20230110515A (ko) 2023-07-24
AU2021363702A9 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
WO2020212760A3 (en) Compounds and methods for the treatment of ocular disorders
Aragona et al. Modern approach to the treatment of dry eye, a complex multifactorial disease: a PICASSO board review
Jassim et al. Crosstalk between dysfunctional mitochondria and inflammation in glaucomatous neurodegeneration
WO2022084738A3 (en) Compounds and methods for the treatment of ocular disorders
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
MX2020003534A (es) Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
MX2023004539A (es) Compuestos y metodos para el tratamiento de trastornos oculares.
MX2023004538A (es) Compuestos y metodos para el tratamiento de trastornos oculares.
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201490277A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
CL2025001153A1 (es) Agentes de arni para inhibir la expresión de la proteína quinasa dm1 (dmpk)
ECSP22086300A (es) Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas
MX2021016055A (es) Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis.
AR033151A1 (es) Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
Chen et al. Nonsteroidal anti-inflammatory drugs for retinal neurodegenerative diseases
EP3416617B1 (en) Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
AR092842A1 (es) Tratamiento de enfermedades inflamatorias oculares usando laquinimod
MX2022013665A (es) Composiciones y metodos heterodimeros para el tratamiento de trastornos oculares.
RU2020119228A (ru) Соединения, композиции и способы лечения нарушений со стороны органа зрения и заболеваний кожи
RU2672564C2 (ru) Способы лечения и предотвращения заболеваний глаз, расстройств и патологических состояний меланином и аналогами, предшественниками и производными меланина
CL2025001428A1 (es) Composiciones farmacéuticas para administración ocular
WO2017152129A3 (en) Treatment of glaucoma and/or retinal diseases and formulations useful therefore
EP4308708A4 (en) OCULAR ADMINISTRATION OF THERAPEUTIC AGENTS
WO2023067387A3 (en) Compounds and methods for the treatment of dermal and ocular disorders